[1] |
WANG Dan, DONG Duo, TIAN Chunhua.
Course of development of pharmocovigilance systems in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 735-740.
|
[2] |
WANG Dan, REN Jingtian, WU Guizhi, XIONG Weiyi, TANG Ren, PANG Yu, FAN Rong, YANG Le.
Significance of Good Pharmacovigilance Practice in the Construction of China Pharmacovigilance System
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 501-503.
|
[3] |
SHEN Mengqiu, LI Ming, WANG Jiayu, GAN Ge, LIU Pengcheng, SUN Jun.
Sampling Investigation of Current Situalion of Pharmacovigilance in Pharmaceutical Manufacturers in Jiangsu Province
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 133-137.
|
[4] |
WANG Dan, REN Jingtian, DONG Duo, PENG Lili, LIU Wei.
Trend Analysis of Ten-year Annual Reports on Adverse Drug Reaction Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(5): 276-283.
|
[5] |
YUAN Lin, GAOYan, LU Changfei.
Preliminary Thinking on the Establishment of Pharmacovigilance System in China
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 749-752.
|
[6] |
ZHAO Xia, LENG Meiling, WANG Peng, LI Xinling, CAO Lujuan, TIAN Chunhua, LIU Cuili.
Research on Current Status and Countermeasures of Information Collection on Adverse Drug Reactions by Drug Manufacturers from Medical Institutions in China
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(11): 652-657.
|
[7] |
SUN Jun, HUANG Qian-qian, GAN Ge, WANG Jia-yu.
Discussion on the Strategy of Drug Manufacturers to Deal with the Adverse Drug Event Clustering Signal
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(11): 671-674.
|
[8] |
DONG Duo ,WU Gui-zhi, WANG Tao, LIU Jia,XIONG Wei-yi,WANG Dan .
The Enlightens on Carrying out Reporting Responsibility of Manufactures in China from Reviewing the Post Marketing Surveillance System in US
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(10): 607-610.
|
[9] |
ZHAO Shi-dan, GAO Xu-guang, DAI Yun-peng, CAO Fei, LIU Li-min, LI Bai-qiang, LU Zhong-ping .
Preliminary Exploration for Construction of Adverse Drug Reaction/Event Sentinel Surveillance in Heilongjiang Province
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(5): 269-271.
|
[10] |
YU Chao, XU Yu-ming, LI Xin-ling, WANG Ling, ZHOU Juan, WAN Kai-hua, XU Jin, YUAN Xin-dong .
Demand Investigation of Interconnection between Hospital Information System and National Adverse Drug Reaction Monitoring System in China
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(3): 154-158.
|
[11] |
WANG Dan, DONG Duo.
Discussion on the Key Drug Monitoring in China
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(9): 534-537.
|
[12] |
REN Jing-tian, ZHENG Wen-ke, ZHANG Jun-hua, LEI Xiang, YANG Le, GUO Xiao-xin, SHANG Hong-cai, DU Xiao-xi.
Role of Drug Manufacturers in Post-marketed Drug Risk Management
[J]. Chinese Journal of Pharmacovigilance, 2014, 11(2): 88-93.
|
[13] |
BIAN Lei ,ZHAO Pin ,YANG Yue .
The Research of Patient Direct Reporting in Pharmacovigilance
[J]. Chinese Journal of Pharmacovigilance, 2013, 10(10): 609-613.
|
[14] |
ZHANG Jing ,WANG Peng-yuan ,PANG Yi-sheng ,HOU Yong-fang.
The Adverse Drug Reaction Monitoring In Hospitals
[J]. Chinese Journal of Pharmacovigilance, 2013, 10(1): 54-56.
|
[15] |
LIU Cui-li, TIAN Chun-hua, FENG Hong-yun.
How Medical Institutions to Do Adverse Drug Reaction Monitoring Well
[J]. Chinese Journal of Pharmacovigilance, 2012, 9(4): 224-226.
|